Download our whitepaper,
Parkinson’s Disease Trials: Motor
and Non-Motor Symptom
Evaluation
What's Inside:
- UPDRS scoring and clinical assessment tools.
- Non-motor symptom evaluation and quality of life metrics.
- Biomarker development for disease progression.
- Advancements in neuroprotective and restorative therapies.
- Digital endpoints and wearable monitoring integration.
- Trial design strategies for early-stage Parkinson’s.
Access your complimentary whitepaper today:
Parkinson’s Disease
Parkinson’s Disease is a neurological condition characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability, as well as non-motor symptoms including cognitive impairment, mood disorders, and autonomic dysfunction.
It is a progressive disorder that can affect individuals of all ages, although it is more common in older adults, and typically requires long-term management.
Over time, research has advanced from viewing Parkinson’s Disease merely as a motor disorder to understanding its complex mechanisms involving genetic, neurobiological, and environmental factors.
This evolving understanding has been crucial in developing current therapeutic approaches that aim to manage symptoms, improve overall functioning, and address the multifaceted components of the disease.
iNGENū’s team of experienced researchers and clinicians specializes in designing and conducting innovative studies. By leveraging enhanced trial design and comprehensive patient-centric strategies, we are committed to accelerating the development of new treatments for Parkinson’s Disease.
15%
of people with Parkinson’s Disease have a family history of the disease
10–15%
of people diagnosed with Parkinson’s Disease experience symptoms before the age of 60
60%
of dopamine-producing neurons are lost by the time Parkinson’s Disease becomes noticeable
Our clinical team has over
120
years of combined clinical trial experience